Open AccessSTK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data
Author(s) -
Zhenxin Wang,
Guoqing Zhang,
Zhongcheng Li,
Jin Li,
Huili Ma,
Ailian Hei,
Shunchang Jiao,
Yi Hu,
Shengjie Sun,
Liangliang Wu,
Ji Zhou,
Yu Wang,
Ellen He,
Sven Skog
Publication year - 2021
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2020-0130
Subject(s) - medicine , proportional hazards model , lung cancer , biomarker , oncology , carcinoma , lung , prospective cohort study , chemotherapy , survival analysis , biology , biochemistry
Aim: A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs).Patients & methods: The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017. Results: Kaplan–Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS. Conclusion: STK1p is helpful in predicting OS of early/middle stages (I–IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs.